A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
A putative tumor suppressor locus on the short arm of human chromosome 9 has been localized to a region of less than 40 kilobases by means of homozygous deletions in melanoma cell lines. This region contained a gene, Multiple Tumor Suppressor 1 (MTS1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase 4. MTS1 was homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines that carried at least one copy of MTS1 frequently carried nonsense, missense, or frameshift mutations in the gene. These findings suggest that MTS1 mutations are involved in tumor formation in a wide range of tissues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Within months of its discovery, the INK4a (CDKN2A) and the genetically linked INK4b gene (CDKN2B) (36) were implicated in a reverse genetic screen to play tumor suppressive roles in familial melanoma (37).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [37]
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
A novel cyclin encoded by a bcl1-linked candidate oncogene
Motokura, T., Bloom, T., Kim, H. G., Jüppner., H., Ruderman, J. V., Kronenberg, H. M., & Arnold, A. (1991) · Nature · doi:10.1038/350512a0 · Cited by 1,265
Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
p53: At the Crossroads of Molecular Carcinogenesis and Risk Sssessment
Harris, C. C. (1993) · Science · doi:10.1126/science.8266092 · Cited by 475
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma.
Rosenberg, C. L., Wong, E., Petty, E. M., Bale, A. E., Tsujimoto, Y., Harris, N. L., & Arnold, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9638 · Cited by 432
Research works printed but not linked: 1
- Weaver-Feldhaus, J., Proceedings of the National Academy of Sciences of the United States of America 91: 7563 (1994).
Cited by
Items 401–500 of 1,005
Benedict, W. F., Lerner, S. P., Zhou, J., Shen, X., Tokunaga, H., & Czerniak, B. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202452 · Cited by 131
Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells
Yang, C.-T., You, L., Yeh, C.-C., Chang, J. W.-C., Zhang, F., McCormick, F., & Jablons, D. M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.8.636 · Cited by 126
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma
Guldberg, P., Straten, P. T., Ahrenkiel, V., Seremet, T., Kirkin, A. F., & Zeuthen, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202486 · Cited by 124
“…genes p16INK4/CDKN2 and PTEN/MMAC1 on 9p and 10q, respectively, have been demonstrated in signi®cant proportions of melanoma lesions and cell lines (Kamb et al., 1994; Bartkova et al., 1996; Castellano et al., 1997; Guldberg et al., 1997; Walker et al., 1998; Tsao et al., 1998), and the AIM1 gene…”
BackgroundInduction of p21 WAF1/CIP1 and Inhibition of Cdk2 Mediated by the Tumor Suppressor p16 INK4a
Mitra, J., Dai, C. Y., Somasundaram, K., El-Deiry, W. S., Satyamoorthy, K., Herlyn, M., & Enders, G. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3916 · Cited by 126
Lonardo, F., Rusch, V. W., Langenfeld, J. E., Dmitrovsky, E., & Klimstra, D. S. (1999) · PubMed · Cited by 135
Sacks, P. G. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00049486 · Cited by 129
Comparative genomic in situ hybridization of colon carcinomas with replication error.
Schlegel, J., Stumm, G., Scherthan, H., Bocker, T., Zirngibl, H., Rüschoff, J., & Hofstädter, F. (1995) · PubMed · Cited by 123
Mammalian anti proliferative signals and their targets
Massagué, J., & Polyák, K. (1995) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(95)90059-4 · Cited by 130
Health effects from stratospheric ozone depletion and interactions with climate change
de Gruijl, F. R., Longstreth, J. D., Norval, M., Cullen, A. P., Slaper, H., Kripke, M. L., Takizawa, Y., & van der Leun, J. C. (2003) · Photochemical & Photobiological Sciences · doi:10.1039/b211156j · Cited by 141
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression
Nozaki, M., Tada, M., Kobayashi, H., Zhang, C. L., Sawamura, Y., Abe, H., Ishii, N., & Meir, E. G. V. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.2.124 · Cited by 122
Molecular analysis of oral lichen planus. A premalignant lesion?
Zhang, L., Michelsen, C., Cheng, X., Zeng, T., Priddy, R., & Rosin, M. P. (1997) · Europe PMC (PubMed Central) · Cited by 122
Salvesen, H. B., Das, S., & Akslen, L. A. (2000) · PubMed · Cited by 121
Frequent Abnormalities of the P15 and P16 Genes in Mycosis Fungoides and Sezary Syndrome
Scarisbrick, J. J., Woolford, A. J. ‐., Calonje, E. J., Photiou, A., Ferreira, S., Orchard, G. E., Russell‐Jones, R., & Whittaker, S. J. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01682.x · Cited by 133
Genetics and the common cancers
Peto, J., & Houlston, R. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00255-6 · Cited by 158
Villuendas, R., Sánchez‐Beato, M., Martínez, J. C., Sáez, A. I., Martínez–Delgado, B., García, J. F., Mateo, M. S., Sánchez‐Verde, L., Benitez, J. J., Martínez, P., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65630-1 · Cited by 132
Stability and folding of the tumour suppressor protein p16 1 1Edited by J. Karn
Tang, K. S., Guralnick, B. J., Wang, W. K., Fersht, A. R., & Itzhaki, L. S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2420 · Cited by 134
“The mutation P114L was identi®ed in melanoma cell line (Kamb et al., 1994) was unable to bind CDK4 or CDK6 (Harland et al., 1997).”
BackgroundNoda, I., Fujieda, S., Seki, M., Tanaka, N., Sunaga, H., Ohtsubo, T., Tsuzuki, H., Fan, G., & Saitô, H. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<279::aid-ijc18>3.0.co;2-n · Cited by 73
Differential gene expression in leiomyosarcoma
Skubitz, K. M., & Skubitz, A. P. N. (2003) · Cancer · doi:10.1002/cncr.11586 · Cited by 120
Hui, R., Macmillan, R. D., Kenny, F. S., Musgrove, E. A., Blamey, R. W., Nicholson, R. I., Robertson, J. F. R., & Sutherland, R. L. (2000) · PubMed · Cited by 143
The Role of EXT1 in Nonhereditary Osteochondroma: Identification of Homozygous Deletions
Hameetman, L., Szuhai, K., Yavas, A., Knijnenburg, J., van Duin, M., van Dekken, H., Taminiau, A. H. M., Cleton-Jansen, A. M., Bovée, J. V. M. G., & Hogendoorn, P. C. W. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk067 · Cited by 120
Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia.
Yamada, Y., Hatta, Y., Murata, K., Sugawara, K., Ikeda, S., Masanobu, M. I. N. E., Maeda, T., Hirakata, Y., Kamihira, S., Tsukasaki, K., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1778 · Cited by 127
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Côté, R. J., & Roy‐Burman, P. (1995) · Europe PMC (PubMed Central) · Cited by 120
Wu, D., Hiroshima, K., Matsumoto, S., Nabeshima, K., Yusa, T., Ozaki, D., Fujino, M., Yamakawa, H., Nakatani, Y., Tada, Y., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpt94jvwihbkrd · Cited by 119
The Gene for Multiple Familial Trichoepithelioma Maps to Chromosome 9p21
Harada, H., Hashimoto, K., & Ko, M. S. H. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12297860 · Cited by 125
Cyclin E, a redundant cyclin in breast cancer
Gray-Bablin, J., Zalvide, J. B., Fox, M., Knickerbocker, C. J., DeCaprio, J. A., & Keyomarsi, K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15215 · Cited by 129
Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa, R., Furnari, F. B., Lin, H., Arap, W., Berger, M. S., Cavenee, W. K., & Huang, H. (1995) · PubMed · Cited by 139
Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood
Stegmaier, K., Pendse, S., Barker, G., Bray-Ward, P., Ward, D., Montgomery, K., Krauter, K., Reynolds, C., Sklar, J., & Donnelly, M. (1995) · Blood · doi:10.1182/blood.v86.1.38.bloodjournal86138 · Cited by 119
Walker, D., Duan, W., Popovic, E. A., Kaye, A. H., Tomlinson, F. H., & Lavin, M. F. (1995) · PubMed · Cited by 125
Aggerholm, A., Guldberg, P., Hokland, M., & Hokland, P. (1999) · PubMed · Cited by 134
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia
Kawamura, M., Ohnishi, H., Guo, S.-X., Sheng, X., Minegishi, M., Hanada, R., Horibe, K., Hongo, T., Kaneko, Y., Bessho, F., et al. (1999) · Leukemia Research · doi:10.1016/s0145-2126(98)00146-5 · Cited by 139
Inactivation of P16Ink4 in Hepatocellular Carcinoma
Hui, A., Sakamoto, M., Kanai, Y., Ino, Y., Gotoh, M., Yokota, J., & Hirohashi, S. (1996) · Hepatology · doi:10.1002/hep.510240319 · Cited by 123
González, M. V., Artímez, M. L., Rodrigo, L., López‐Larrea, C., Menéndez, M., Álvarez, V., Pérez, R., Fresno, M., Pérez, M. J., Sampedro, A., et al. (1997) · Journal of Clinical Pathology · doi:10.1136/jcp.50.3.212 · Cited by 117
Ovarian clear cell adenocarcinoma: a continuing enigma: Table 1
Tan, D. S. P., & Kaye, S. B. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040030 · Cited by 134
Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma
Dehn, D. L., Torkko, K. C., & Shroyer, K. R. (2007) · Cancer · doi:10.1002/cncr.22425 · Cited by 116
Suzuki, T., Narita, T., Uchida-Toita, M., & Yoshida, M. (1999) · Virology · doi:10.1006/viro.1999.9760 · Cited by 131
Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.
Guan, K. L., Jenkins, C. W., Li, Y., O'Keefe, C. L., Noh, S., Wu, X., Zariwala, M., Matera, A. G., & Xiong, Y. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.1.57 · Cited by 118
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
Kannan, K., Sharpless, N. E., Xu, J., O'Hagan, R. C., Bosenberg, M., & Chin, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336397100 · Cited by 116
Hodges, A., & Smoller, B. R. (2002) · Modern Pathology · doi:10.1097/01.mp.0000032536.48264.d1 · Cited by 128
“Seventy-five percent of melanoma cell lines have been found to contain mutant or lost p16 gene, and germ-line mutations have been found in the p16 gene in patients with multiple primary melanomas (13, 14).”
BackgroundLong non-coding RNAs and their implications in cancer epigenetics
Beckedorff, F., Amaral, M. S., DeOcesano-Pereira, C., & Verjovski‐Almeida, S. (2013) · Bioscience Reports · doi:10.1042/bsr20130054 · Cited by 119
Liu, C. X., Musco, S., Lisitsina, N. M., Forgacs, E., Minna, J. D., & Lisitsyn, N. A. (2000) · PubMed · Cited by 117
Zhang, H., Chen, Z.-H., & Savarese, T. M. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00157-3 · Cited by 125
Nosaka, K., Maeda, M., Tamiya, S., Sakai, T., Mitsuya, H., & Matsuoka, M. (2000) · PubMed · Cited by 133
The genetics of transitional cell carcinoma: progress and potential clinical application
Knowles, M. A. (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00217.x · Cited by 137
Fournel, M., Sapieha, P. S., Beaulieu, N., Besterman, J. M., & MacLeod, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24250 · Cited by 132
Hangaishi, A., Ogawa, S., Imamura, N., Miyawaki, S., Miura, Y., Uike, N., Shimazaki, C., Emi, N., Takeyama, K., Hirosawa, S., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4949.bloodjournal87124949 · Cited by 115
Nam, E. J., Kim, J. W., Hong, J. W., Jang, H. S., Lee, S. Y., Jang, S. Y., Lee, D. W., Kim, S. W., Kim, J., Kim, Y. T., et al. (2008) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2008.19.3.162 · Cited by 114
Association of K-ras mutations with p16 methylation in human colon cancer
Guan, R. J., Fu, Y., Holt, P. R., & Pardee, A. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70009-0 · Cited by 151
The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation
Gilbert, J., Gore, S. D., Herman, J. G., & Carducci, M. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0297 · Cited by 121
Cutaneous melanoma susceptibility and progression genes
DESNOO, F., & Hayward, N. K. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.033 · Cited by 127
Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma
Meijer, D., de Jong, D., Pansuriya, T. C., van den Akker, B. E., Picci, P., Szuhai, K., & Bovée, J. V. M. G. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21974 · Cited by 115
“Although p16 point mutations have been identified to play a role in some tumor types like melanoma (Hussussian et al., 1994; Kamb et al., 1994) and pancreatic adenocarcinoma (Caldas et al., 1994), they are rare in most primary tumors (Cairns et al., 1994).”
BackgroundNatarajan, E., Saeb, M., Crum, C. P., Woo, S. B., McKee, P. H., & Rheinwald, J. G. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63677-2 · Cited by 124
Xing, E. P., Nie, Y., Wang, L., Yang, G.-Y., & Yang, C. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.1.77 · Cited by 115
“p15 INK4b can displace p27 from the cyclin D-CDK4 complex, thereby promoting p27 binding and inactivation of cyclin E-CDK2 ( 5 ).”
BackgroundNobori, T., Takabayashi, K., Tran, P., Orvis, L., Batova, A., Yu, A. L., & Carson, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.6203 · Cited by 113
Involvement of the INK4a/Arf gene locus in senescence
Collins, C. J., & Sedivy, J. M. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00048.x · Cited by 113
Imoto, I., Izumi, H., Yokoi, S., Hosoda, H., Shibata, T., Hosoda, F., Ohki, M., Hirohashi, S., & Inazawa, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4437 · Cited by 113
“All cell lines were maintained as previously described (13).”
Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Frye, C., Eeles, R. A., Orlow, I., Lacombe, L., Ponce-Castañeda, V., LIANES, P., & Latres, E. (1995) · Europe PMC (PubMed Central) · Cited by 127
Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V. W., Nowak, J. A., McIntire, D. D., Slamon, D. J., Gazdar, A. F., & Minna, J. D. (1994) · CHEST Journal · doi:10.1378/chest.106.6_supplement.377s · Cited by 113
Fåhræus, R., & Lane, D. P. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2106 · Cited by 125
“Of these kinase inhibitors, only p16INK4a function is lost at a high frequency in human cancers (Kamb et al., 1994; Ranade et al., 1995; Hall and Peters, 1996).”
BackgroundFogt, F., Vortmeyer, A. O., Goldman, H., Giordano, T. J., Merino, M. J., & Zhuang, Z. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90222-2 · Cited by 112
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS
Leone, G. G. M., Voso, M. T., Teofili, L., & Lübbert, M. (2003) · Clinical Immunology · doi:10.1016/s1521-6616(03)00207-9 · Cited by 123
Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation
Nakao, Y., Yang, X., Yokoyama, M., Ferenczy, A. S., Tang, S.-C., Pater, M. M., & Pater, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.243 · Cited by 123
“Therefore, the loss of functional pJ6 disrupts the pattern of cellular gene expression and initiates carcinogenesis through the deregulation of the cell cycle (Kamb et al, 1994).”
BackgroundJin, M., Inoue, S., Umemura, T., Moriya, J., ARAKAWA, M., Nagashima, K., & Kato, H. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00225-2 · Cited by 112
Viallard, J.-F., Lacombe, F., Belloc, F., Pellegrin, J., & Reiffers, J. J. (2001) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(01)00087-7 · Cited by 155
Requirement of Cyclin E-Cdk2 Inhibition in p16 INK4a -Mediated Growth Suppression
Jiang, H., Chou, H. S., & Zhu, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5284 · Cited by 113
“At least one regulator of cyclin D1-Cdk4, the cyclin-dependent kinase inhibitor p16, is also a known tumor suppressor gene product (17, 28) whose function is frequently lost in melanoma and in a variety of other cancers (for a review, see reference 9).”
BackgroundHMGIC expression in human adult and fetal tissues and in uterine leiomyomata
Gattás, G. J. F., Quade, B. J., Nowak, R. A., & Morton, C. C. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199908)25:4<384::aid-gcc11>3.0.co;2-d · Cited by 144
Griewank, K., Wiesner, T., Murali, R., Pischler, C., Müller, H., Koelsche, C., Möller, I., Franklin, C., Cosgarea, I., Sucker, A., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.146 · Cited by 118
The Mammalian Cell Cycle: An Overview
Harper, J. V., & Brooks, G. (2004) · Humana Press eBooks · doi:10.1385/1-59259-857-9:113 · Cited by 150
Molecular pathology of head‐and‐neck cancer
Kim, M. M., & Califano, J. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20379 · Cited by 126
Maleno, I., López‐Nevot, M. Á., Cabrera, T., Jose, S., & Garrido, F. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0296-0 · Cited by 122
p16INK4a and the control of cellular proliferative life span
Huschtscha, L. I. (1999) · Carcinogenesis · doi:10.1093/carcin/20.6.921 · Cited by 111
Thiagalingam, S., Foy, R. L., Cheng, K., Lee, H. J., Thiagalingam, A., & Ponte, J. F. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00012 · Cited by 124
Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K., & Huang, H.-J. S. (1995) · PubMed · Cited by 120
Evaluation of alternative methods of cervical cancer screening for resource-poor settings
Denny, L., Kuhn, L., Pollack, A. E., Wainwright, H., & Wright, T. C. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<741::aid-cncr4>3.0.co;2-w · Cited by 250
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
Freedberg, D. E., Rigas, S. H., Russak, J., Gai, W., Kaplow, M., Osman, I., Turner, F., Randerson-Moor, J. A., Houghton, A., Busam, K., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn157 · Cited by 109
“Evidence of a role for p16 in human melanoma includes frequent genetic and epigenetic alterations in human melanoma specimens (4–6) and cell lines (7), the presence of germline mutations in this gene in 10%–50% of familial melanoma cases (8–11), and data from murine models in which the specific deletion of exon 1α com…”
BackgroundChromosomal imbalances in noninvasive papillary bladder neoplasms (pTa).
Zhao, J., Richter, J., Wagner, U., Roth, B., Schraml, P., Zellweger, T., Ackermann, D., Schmid, U., Moch, H., Mihatsch, M. J., et al. (1999) · PubMed · Cited by 110
Balázs, M., Ádám, Z., Treszl, A., Bégány, Á., Hunyadi, J., & Ádány, R. (2001) · Cytometry · doi:10.1002/cyto.1131 · Cited by 109
Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer
Kwei, K. A., Bashyam, M. D., Kao, J., Ratheesh, R., Reddy, E. C., Kim, Y. H., Montgomery, K., Giacomini, C. P., Choi, Y.-L., Chatterjee, S., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000081 · Cited by 109
“Mapping CNAs has become an important starting point for discovering new cancer genes, and indeed led to the original identification of CDKN2A and SMAD4 as TSGs [3] [4].”
BackgroundMolecular Mechanisms and Pathways in Bladder Cancer Development and Progression
Jung, I., & Messing, E. M. (2000) · Cancer Control · doi:10.1177/107327480000700401 · Cited by 125
Fujiwara, Y., Chi, D. D., Wang, H., Keleman, P., Morton, D. L., Turner, R. R., & Hoon, D. S. �. (1999) · PubMed · Cited by 112
P16 UV mutations in human skin epithelial tumors
Soufir, N., Molès, J., Vilmer, C., Moch, C., VEROLA, O., Rivet, J., Tesnière, A., Dubertret, L., & Basset‐Séguin, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202915 · Cited by 124
“The two double substitutions were previously described as UV mutations in melanoma cell lines and in sporadic melanoma (Kamb et al., 1994; Pollock et al., 1995; Healy et al., 1996).”
BackgroundCheng, Y., Poulos, N. E., Lung, M. L., Hampton, G. M., Bao-xiang, O., Lerman, M. I., & Stanbridge, E. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3042 · Cited by 107
Bullrich, F., MacLachlan, T. K., Sang, N., Druck, T., Veronese, M. L., Allen, S. L., Chiorazzi, N., Koff, A., Heubner, K., & Croce, C. M. (1995) · PubMed · Cited by 123
Hypermethylation of gene promoters in hematological neoplasia
Chim, C. S., Liang, R. H. S., & Kwong, Y. (2002) · Hematological Oncology · doi:10.1002/hon.694 · Cited by 112
Devilee, P., Cleton-Jansen, A., & Cornelisse, C. J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02416-7 · Cited by 106
Ct, L., Capodieci, P., Osman, I., Fazzari, M. J., Ferrara, J., Scher, H. I., & Cordon‐Cardo, C. (1999) · PubMed · Cited by 111
Nagai, H., Negrini, M., Carter, S. L., Gillum, D. R., Rosenberg, A., Schwartz, G. F., & Croce, C. M. (1995) · PubMed · Cited by 106
How many tumor suppressor genes are involved in human lung carcinogenesis?
Kohno, T. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1403 · Cited by 105
Mælandsmo, G., Flørenes, V., Hovig, E., Øyjord, T., Engebraaten, O., Holm, R., Børresen, A.-L., & Fodstad, Ø. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.181 · Cited by 106
Genomic Alterations of the p19ARF Encoding Exons in T-Cell Acute Lymphoblastic Leukemia
Gardie, B., Cayuela, J.-M., Martini, S., & Sigaux, F. (1998) · Blood · doi:10.1182/blood.v91.3.1016 · Cited by 106
Targeting Oncogenic Drivers and the Immune System in Melanoma
McArthur, G. A., & Ribas, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.5568 · Cited by 105
Our changing view of the genomic landscape of cancer
Bell, D. W. (2009) · The Journal of Pathology · doi:10.1002/path.2645 · Cited by 130
Straume, O., Smeds, J., Kumar, R., Hemminki, K., & Akslen, L. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64174-0 · Cited by 124
Tumor suppressor genes and related molecules in leiomyosarcoma.
Tos, A. P. D., Maestro, R., Doglioni, C., Piccinin, S., Libera, D. D., Boiocchi, M., & Fletcher, C. D. �. (1996) · Europe PMC (PubMed Central) · Cited by 105
Heerema, N. A., Sather, H. N., Sensel, M. G., Liu‐Mares, W., Lange, B. J., Bostrom, B., Nachman, J. B., Steinherz, P. G., Hutchinson, R. J., Gaynon, P. S., et al. (1999) · PubMed · Cited by 114
p16 and p21WAF1 Protein Expression in Melanocytic Tumors by Immunohistochemistry
Sparrow, L. E., Eldon, M. J., English, D. R., & Heenan, P. J. (1998) · The American Journal of Dermatopathology · doi:10.1097/00000372-199806000-00006 · Cited by 105
Epigenetic Regulation of Genomic Stability by Vitamin C
Brabson, J. P., Leesang, T. E., Mohammad, S., & Cimmino, L. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.675780 · Cited by 118
Genetic and epigenetic changes in stomach cancer
Yokozaki, H., Yasui, W., & Tahara, E. (2001) · International review of cytology · doi:10.1016/s0074-7696(01)04003-7 · Cited by 112
Bilanges, B., Varrault, A., Basyuk, E. I., Rodríguez, C., Mazumdar, A., Pantaloni, C., Bockaert, J., Theillet, C. G., Spengler, D., & Journot, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202933 · Cited by 104
“However, P16 mutations are rare in sporadic tumors (Cairns et al., 1994) and P16 was found to be more prevalently inactivated by homozygous deletion (Kamb et al., 1994a) or gene silencing (Gonzalez-Zulueta et al., 1995; Herman et al., 1995; Merlo, 1995).”
BackgroundKato, K., Hara, A., Kuno, T., Mori, H., Yamashita, T., Toida, M., & Shibata, T. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-006-0122-8 · Cited by 106
“The p16 gene mapped on the chromosome 9p21 region is known to encode the inhibitor of the cyclin-dependent kinase (CDK) 4/cyclin D complex, which regulates phosphorylation of the retinoblastoma protein (pRb) and controls the cell-cycle progression in the G1/S border (Kamb et al. 1994).”
BackgroundFizzotti, M., Cimino, G. G., Pisegna, S., Alimena, G., Quartarone, C., Mandelli, F., Pelicci, P. G., & Coco, F. L. (1995) · Blood · doi:10.1182/blood.v85.10.2685.bloodjournal85102685 · Cited by 110
Metadata
- Authors
- Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H.
- Affiliations
- Myriad Genetics (US)
- Memorial Sloan Kettering Cancer Center (US)
- Cross Cancer Institute (CA)
- National Institutes of Health (US)
- University of Utah (US)
- Venue
- Science
- Published
- 1994-04-15
- Volume
- 264
- Issue
- 5157
- Pages
- 436-440
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1983348452
- Cited by
- 2,751
- References
- 26
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 18 · 2023: 12 · 2022: 22 · 2021: 31 · 2020: 24 · 2019: 23 · 2018: 34 · 2017: 45 · 2016: 20 · 2015: 32 · 2014: 31 · 2013: 44 · 2012: 54
- FWCI
- 115.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ca048711-05)
- National Cancer Institute (CA 48711)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- CDKN2A, p16, tumor suppressor, chromosome 9p, homozygous deletion, melanoma cell lines, CDK4, cell cycle regulation, genetic mutations
- MeSH terms
- Base Sequence, Carrier Proteins, Cell Cycle, Chromosomes, Human, Pair 9, Cosmids, Exons, Humans, Introns, Melanoma, Molecular Sequence Data, Mutation, Neoplasms, Proto-Oncogene Proteins, Tumor Cells, Cultured, Genes, Tumor Suppressor, Gene Deletion, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.